journal article·2023-11-01

pH-Responsive and Actively Targeted Metal–Organic Framework Structures for Multimodal Antitumor Therapy and Inhibition of Tumor Invasion and Metastasis

WeiLu Jia, Bin Jin, WenJing Xu, ShiWei Liu, XinYu Mao, Hao Peng, YeWei Zhang

ACS Applied Materials & Interfaces· Volume 15· Issue 43
Publisher page

Abstract

Multimodal treatment is an important tool to overcome tumor drug resistance. The reactive oxygen species (ROS) generated by photodynamic therapy (PDT) can directly play a killing role on tumor cells, which has the advantages of repeatable treatment and no drug resistance. However, its therapeutic oxygen consumption and destruction of tumor microvessels lead to hypoxia in tumor tissues, and hypoxia leads to overexpression of the receptor tyrosine kinase (c-MET) and vascular endothelial growth factor receptor (VEGFR). Overexpression of these two receptors leads to increased tumor invasiveness and metastasis. The molecularly targeted drug cabozantinib (CAB) has multiple targets, including anti-c-MET and VEGFR, to inhibit the development of hepatocellular carcinoma (HCC). In this study, our team designed a pH-sensitive nanoparticle CAB/Ce6@ZIF-8@PEG-FA (CCZP) loaded with CAB and Ce6, which exerted a multimodal therapeutic effect of PDT and molecularly targeted therapy by laser irradiation, and the PDT-induced overexpression of MET and VEGFR could also be inhibited by the target of CAB, thus reducing the invasive tumor cells metastasis. In summary, CCZP gives full play to the advantages of both drugs, exerting multimodal treatment while reducing HCC invasion and metastasis, providing a safe, potential approach to clinical treatment.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Cancer, Hypoxia, and Metabolism

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Medical School, Southeast University, Nanjing 210009, China

Department of Hepatobiliary Surgery, The Second Hospital of Shandong University, Jinan, Shandong 250000, China

Hepatopancreatobiliary Center, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210009, China

Funding

Natural Science Foundation of Jiangsu Province · National Natural Science Foundation of China · Jiangsu Provincial Key Research and Development Program

References (47)

Show source-provided references
1. 10.1056/NEJMra171326310.1056/NEJMra1713263 ↗
2. 10.1053/j.gastro.2021.12.27610.1053/j.gastro.2021.12.276 ↗
3. 10.1038/nrclinonc.2017.16610.1038/nrclinonc.2017.166 ↗
4. 10.1038/nrc336610.1038/nrc3366 ↗
5. 10.1039/D0CS01370F10.1039/D0CS01370F ↗
6. 10.1038/nrc107010.1038/nrc1070 ↗
7. 10.1039/C6CS00271D10.1039/C6CS00271D ↗
8. 10.1039/C2CS35216H10.1039/C2CS35216H ↗
9. 10.1039/c3cs35531d10.1039/c3cs35531d ↗
10. 10.1021/acs.chemrev.1c0038110.1021/acs.chemrev.1c00381 ↗
11. 10.3322/caac.2011410.3322/caac.20114 ↗
12. 10.1016/j.biomaterials.2018.09.03310.1016/j.biomaterials.2018.09.033 ↗
13. 10.1016/S1535-6108(03)00085-010.1016/S1535-6108(03)00085-0 ↗
14. 10.1038/s41571-020-0377-z10.1038/s41571-020-0377-z ↗
15. 10.1038/sj.onc.120940910.1038/sj.onc.1209409 ↗
16. 10.1016/j.jhep.2013.09.00910.1016/j.jhep.2013.09.009 ↗
17. 10.1016/j.jhep.2016.05.00710.1016/j.jhep.2016.05.007 ↗
18. 10.1158/0008-5472.CAN-06-060410.1158/0008-5472.CAN-06-0604 ↗
19. 10.1038/nrm191110.1038/nrm1911 ↗
20. 10.1016/j.ccr.2009.01.02710.1016/j.ccr.2009.01.027 ↗
21. 10.1158/2159-8290.CD-11-024010.1158/2159-8290.CD-11-0240 ↗
22. 10.3322/caac.2141110.3322/caac.21411 ↗
23. 10.1038/s41392-020-00264-x10.1038/s41392-020-00264-x ↗
24. 10.1038/s41572-020-00240-310.1038/s41572-020-00240-3 ↗
25. 10.1111/liv.1510110.1111/liv.15101 ↗
26. 10.1056/NEJMoa070885710.1056/NEJMoa0708857 ↗
27. 10.1158/1078-0432.CCR-13-262010.1158/1078-0432.CCR-13-2620 ↗
28. 10.1016/j.ctrv.2021.10222110.1016/j.ctrv.2021.102221 ↗
29. 10.1056/NEJMoa171700210.1056/NEJMoa1717002 ↗
30. 10.1093/annonc/mdw65110.1093/annonc/mdw651 ↗
31. 10.1159/00051986710.1159/000519867 ↗
32. 10.1007/s11523-020-00736-810.1007/s11523-020-00736-8 ↗
33. 10.1056/NEJMoa202698210.1056/NEJMoa2026982 ↗
34. 10.1016/j.apsb.2022.03.01010.1016/j.apsb.2022.03.010 ↗
35. 10.1002/adma.20200186210.1002/adma.202001862 ↗
36. 10.1002/adma.20170419610.1002/adma.201704196 ↗
37. 10.1016/j.cclet.2021.09.08410.1016/j.cclet.2021.09.084 ↗
38. 10.1002/adma.20180020210.1002/adma.201800202 ↗
39. 10.1002/adma.20220087110.1002/adma.202200871 ↗
40. 10.1039/C9TB02482D10.1039/C9TB02482D ↗
41. 10.1021/acsnano.2c0551710.1021/acsnano.2c05517 ↗
42. 10.1016/j.colsurfb.2020.11089110.1016/j.colsurfb.2020.110891 ↗
43. 10.1016/j.biomaterials.2020.11976110.1016/j.biomaterials.2020.119761 ↗
44. 10.3390/antiox1009133610.3390/antiox10091336 ↗
45. 10.1038/s41419-022-05022-110.1038/s41419-022-05022-1 ↗
46. 10.1038/s41568-020-00307-z10.1038/s41568-020-00307-z ↗
47. 10.1016/j.stem.2010.11.02810.1016/j.stem.2010.11.028 ↗